Back to Search
Start Over
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
- Source :
- Neuroendocrinology; 2020, Vol. 110 Issue 11/12, p988-993, 6p
- Publication Year :
- 2020
-
Abstract
- Background: Platinum-containing regimens are widely used as first-line chemotherapy for unresectable pancreatic neuroendocrine carcinoma (NEC), but second-line chemotherapies have yet to be established. Objectives: We evaluated the safety and efficacy of everolimus in patients with pancreatic NEC refractory or intolerant to platinum-containing chemotherapy. Methods: This study was a prospective, multicenter, phase II trial in patients with pancreatic NEC after platinum-containing chemotherapy. Everolimus treatment was continued until disease progression or intolerable toxicity was observed. The primary endpoint was progression-free survival (PFS). Results: Participants comprised 25 patients. Median age was 63 years, median PFS was 1.2 months (95% confidence interval [CI] 0.9–3.1 months), median overall survival was 7.5 months (95% CI 3.1–13.5 months), overall response rate was 0%, and disease control rate was 39.1%. Common grade 3/4 adverse events were hyperglycemia (20%), thrombocytopenia (16%), and anemia (16%). Conclusion: The efficacy of everolimus was limited in patients with unresectable pancreatic NEC. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER chemotherapy
EVEROLIMUS
CARCINOMA
PROGRESSION-free survival
Subjects
Details
- Language :
- English
- ISSN :
- 00283835
- Volume :
- 110
- Issue :
- 11/12
- Database :
- Complementary Index
- Journal :
- Neuroendocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 146345185
- Full Text :
- https://doi.org/10.1159/000505550